6. Febr. Zulassungsantrag & Rückmeldung with CREA, the “Association Tiers-Monde” and the “Laboratoire International Associé du CNRS. Zulassungsantrag (Dossier) auch die Publikati- onen aus der frei . zulassung laut EU-Gesetz. but bred at different laboratories – the labo-. stehen allen Antragstellern offen, die beim BVL einen Zulassungsantrag mit Deutschland als. zRMS zu stellen .. Such effects shown in labo- ratory studies on.

Author: Salmaran Nahn
Country: Poland
Language: English (Spanish)
Genre: Literature
Published (Last): 5 March 2010
Pages: 236
PDF File Size: 9.30 Mb
ePub File Size: 12.13 Mb
ISBN: 120-1-54927-679-7
Downloads: 40954
Price: Free* [*Free Regsitration Required]
Uploader: Tygohn

“Orange Week” at the University

Die wichtigsten Themen der Woche! Auf welche Aktien setzen? Wirtschaftspolitik Forumsuche in Titel Volltext Aktie. Das alte Jahr zu Ende geht Livent – Lithium spin-off von FMC.

Tages-Trading-Chancen am Zulzssungsantrag den Was ist dran an der Geschichte von der “Fast-Keilerei”? Deutsche Small Caps – Basisinvestments eines Langfristdepots.

Gold und Silber vor neuen Allzeithochs Neujahrsansprache der Bundeskanzlerin im Wortlaut. Soldaten sollen kostenlos Bus und Bahn fahren 1. Platz vorher Wertpapier Kurs Perf. Was Labopharm zubieten hat: In February, the latest month for which data is available, our product was the best selling once-daily tramadol product in four of the five largest European markets.

Patients need rapid improvement of their depressive symptoms and may experience insomnia and agitation. Accordingly, we are optimistic about the prospects for our formulation in the market for antidepressants. Growth in the broader tramadol market 1 was particularly strong in France and Spain, where market share in February reached 6. Product Launched in Poland – Labopharm’s product was launched in Poland by its marketing partner for that country.

Food and Drug Administration’s FDA decision on its once-daily tramadol formulation to the next supervisory level. Labopharm’s continuation of the appeal process followed the completion of additional statistical analysis of existing data per the Agency’s suggestion as a means to potentially satisfy its requirements for regulatory approval. The Company believes that the additional analysis confirms the conclusions of efficacy of its once-daily tramadol formulation as demonstrated in previous analyses that were included in ,abo New Drug Application NDA and additional submissions thereafter.

In addition to achieving statistical significance for the primary endpoint p value of 0. Moreover, the study demonstrated that once-daily trazodone was statistically superior to placebo by the zulassunngsantrag of the first week of treatment. The Company expects data to be available later this year. Der Zeitpunkt zum Kauf ist ebenfalls ungeeignet. Warten sie noch einige Tage ab. Short interest ist fast auf den niedrigsten Stand seit Nasdaq-listing http: Auch Natcan Investment hat wieder zugelegt auf 5,74million aktien stand April Von Richies vor 14 Minuten.

Und da ist noch Trazadone das auch schon bald den Markt erreicht.

“Orange Week” at the University

Tramadol Potential The number of prescriptions written for tramadol products in the United States — the single largest market for tramadol — has more than doubled in the last decade, surpassing 21 million in The vast majority of these were for multiple zulassugsantrag products that must be taken anywhere from four- to six-times per day.

The potential market for a once-daily tramadol treatment, however, is considerably larger. Compliance with multiple-times daily dosing regimens can be challenging for patients, potentially limiting the efficacy of a drug.

A once-daily formulation of tramadol offers significant value and satisfaction to both patients and physicians through the potential to improve compliance. Overall, the market for tramadol is expected to experience continued strong growth, driven primarily by three factors: As an opioid with additional unique mechanisms of action, tramadol is an excellent option in the treatment of moderate to moderately severe pain, providing effective pain relief without many of the potential side effects seen with stronger opioids; Tramadol is often prescribed for pain related to conditions zupassungsantrag become more prevalent with age, such as osteoarthritis.


Antwort auf Beitrag Nr.: Achtung, jetzt geht die Post ab!

Die Zulassung ist bald da. Das Warten hat sich gelohnt!!!!! Food and Drug Administration FDA regarding its most recent appeal of the decision in the Agency’s Approvable Letter for its once-daily tramadol formulation through the Formal Dispute Resolution process. However, he suggested a regulatory path forward. Throckmorton has suggested that the Company submit the analysis put forward by Dr.

Jenkins in his letter of earlier this year. In the response, the FDA has concluded that a positive finding using this analysis could provide the needed assurance to support the efficacy of Labopharm’s once-daily tramadol. Following resolution of any issues with labeling, such a finding would lead to the approval of the product. The Company expects to submit the complete response before the end of the week and the FDA has agreed to conduct its review of the response in a timely basis.

Jenkins suggested we undertake and believe that this is a positive step towards regulatory approval in the U. We continue to believe that the comprehensive data generated by our global clinical trial program demonstrates the efficacy and safety of our once-daily tramadol formulation and that we have met the statutory standards for approval of our formulation.

Jenkins and believes that the findings confirm the conclusions of efficacy of its once-daily tramadol formulation.

About Labopharm’s Once-Daily Tramadol Product Labopharm’s once-daily tramadol product is based on the Company’s proprietary Contramid R technology, which provides a dual matrix delivery system allowing both rapid and sustained drug release that maintains blood levels within the therapeutic range providing a full 24 hours of pain relief. The Company believes that maintaining drug concentrations within the therapeutic range has the advantage of fewer and less severe side effects while maintaining efficacy.

Under its global commercialization program, Labopharm’s once-daily tramadol product has been launched in 11 countries, including the five largest markets in Europe and Canada and is approved in 19 other countries.

Including those countries in which its product has been launched, Labopharm has licensing and distributions in place for more than 50 markets globally.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies.

The Company’s lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development.

Zulassunysantrag vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit www. This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events.

The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, zulassungsantraag the uncertainties related to the regulatory process in various countries for the approval of the Company’s products and the successful commercialization of the products throughout the world if they are approved.

Labopharm Nur geschenkt ist noch billiger – Beiträge pro Seite

Investors should consult the Company’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements. For further information At Labopharm: The complete response centers on the additional analysis of existing data using the methodology put forward by Dr.


Under its aulassungsantrag commercialization program, Labopharm’s once-daily tramadol product has been launched in 12 countries, including the five largest markets in Europe and Canada and is approved in 19 other countries.

Including those countries in which its product has llabo launched, Labopharm has licensing and distribution agreements in place for more than 50 markets globally.

To promote its product in the UK, the Company will engage a contract sales organization and pursue a new licensing and distribution agreement with an appropriate marketing partner. Labopharm will also receive a euromilestone from Recordati upon termination of Recordati’s rights.

The Company is also in discussions to establish a licensing and distribution agreement with a new marketing partner.

The UK is the second largest European market for tramadol products on a zulassungsanteag units basis and one of the fastest growing of the five largest European markets for tramadol products on a standard units basis. Aber mit diesem Link von Babelfish geht es auch. DDS – Nachrichten; Nasdaq: Die Firma ist auch in den Diskussionen, zum einer Genehmigen und Verteilungsvereinbarung mit einem neuen Marketing-Partner herzustellen. Zu mehr Information besuchen Sie bitte www.

Die vorausschauenden Aussagen beziehen Risiken und Ungewissheiten mit ein. Der Leser wird, gewarnt nicht auf diese vorausschauenden Aussagen zu bauen.

Eure Ansichten und Meinungen sind gefragt!! Dauert ja nicht mehr lange bis zum FDA Entscheid!! Die Zulassung ist nur noch eine frage von wenigen Wochen und sehe den aktuellen Kurs als Geschenk an.

Also wenn es diesmal nicht klappt obwohl Labopharm sehr zulassungsangrag mit der FDA zusammengearbeitet hat dann geht es nicht mit rechten Dingen zu. Falls die Zulassung kommt: Short interest ist auf Rekordtief http: Zulaasungsantrag geht Labopharm den richtigen Weg. Incumbent Chief Medical Officer Dr. Sylvie Bouchard has retired from Labopharm Inc.

Supporting development in sub-Saharan Africa

During her tenure at Laob, Dr. Bouchard’s expertise and diligence has zulssungsantrag invaluable to Labopharm’s success to date. On behalf of the Sulassungsantrag and the Board of Directors, I would like to thank her for her very significant contribution to Labopharm and wish her well as a full-time practicing physician. Bouchard will continue to be available to Labopharm to transition the role to Dr. Labopharm said acceptance of the data should lead to an FDA decision on the approval of once-daily Tramadol for use in the United States by January 2, Late last month, the FDA suggested the company submit a previously requested analysis of the drug and said that a positive finding using this analysis could support the efficacy of the product, which could lead to regulatory approval.

The company received notification from the FDA zulassungsanrrag May that its Tramadol treatment would not be approved until certain conditions were met. Loe sees Labopharm filing a new drug application in the third quarter of this year, with regulatory approval in the first quarter of Labopharm’s once-daily version of Tramadol has been launched in 11 countries, including Canada, and is approved in 19 others.

Reporting by Scott Anderson; editing by Rob Wilson.

Back to top